Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM et al (2011) Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet neurology 10(3):213–220
Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279
Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin 64 Band, Verlag von Georg Reimer
Bian H, Van Swieten JC, Leight S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70(19 Pt 2):1827–1835
Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131–144
Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82(4):239–259
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404
Buchhave P, Minthon L, Zetterberg H et al (2012) Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of Tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69(1):98–106
Clark CM, Xie S, Chittams J et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60(12):1696–1702
De Meyer G, Shapiro F, Vanderstichele H et al (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67(8):949–956
Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746
Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9(11):1118–1127
Echavarri C, Caballero MC, Aramendia A, Garcia-Bragado F, Tunon T (2011) Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of Navarra. Anat Rec (Hoboken) 294(7):1191–1197
Emre M, Aarsland D, Brown R, et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 (quiz 1837)
Engelborghs S, De Vreese K, Van de Casteele T et al (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29(8):1143–1159
Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6(2):67–77
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39
Geser F, Martinez-Lage M, Robinson J et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66(2):180–189
Geser F, Robinson JL, Malunda JA et al (2010) Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 67(10):1238–1250
Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76(11):1006–1014
Grossman M, Farmer J, Leight S et al (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 57(5):721–729
Grossman M, Libon DJ, Forman MS et al (2007) Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol 64(11):1601–1609
Hothorn T, Hornik K, van de Wiel MA, Zeileis A (2006) A Lego system for conditional inference. Am Stat 60(3):257–263
Hu W, Chen-Plotkin A, Arnold S et al (2010) Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease. Acta Neuropathol 120(3):385–399
Hu WT, Trojanowski JQ and Shaw LM (2011) Biomarkers in frontotemporal lobar degenerations—progress and challenges. Prog Neurobiol (in press, corrected proof)
Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56(10):1095–1097
Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(6):1630–1645
Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9(1):119–128
Jack CR Jr, Vemuri P, Wiste HJ et al (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68(12):1526–1535
Jellinger KA (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 5(3–4):118–121
Jellinger KA, Attems J (2010) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 119(4):421–433
Khachaturian ZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol 42(11):1097–1105
Kuhn M (2008) Building Predictive Models in R Using the caret. J Stat Softw 28
Ling H, O’Sullivan SS, Holton JL et al (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133(7):2045–2057
Lo RY, Hubbard AE, Shaw LM et al (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68(10):1257–1266
Mackenzie I, Neumann M, Bigio E et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1–4
McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269
Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41(4):479–486
Mollenhauer B, Esselmann H, Trenkwalder C et al (2011) CSF amyloid-beta peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer’s disease. J Alzheimers Dis 24(2):383–391
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10(3):230–240
Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133
Neumann M, Kwong LK, Lee EB et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117(2):137–149
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357(9251):169s–175s
Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6(2):78–87
Olsson A, Vanderstichele H, Andreasen N et al (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51(2):336–345
Parnetti L, Chiasserini D, Bellomo G et al (2011) Cerebrospinal fluid tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord 26(8):1428–1435
Prvulovic D, Hampel H (2011) Amyloid beta (Abeta) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer’s disease. Clin Chem Lab Med 49(3):367–374
R Development Core Team (2011) R: a language and environment for statistical computing. In: R Foundation for statistical computing. Vienna, Austria
Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(9):2456–2477
Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics 12:77
Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24):2197–2204
Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66(2):200–208
Schoonenboom NS, Reesink FE, Verwey NA et al (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78(1):47–54
Shaw LM, Korecka M, Clark CM, Lee VMY, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6(4):295–303
Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology 65(4):403–413
Shi M, Bradner J, Hancock AM et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69(3):570–580
Sinha N, Firbank M, O’Brien JT (2011) Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry. doi:10.1002/gps.2749
Tapiola T, Alafuzoff I, Herukka SK et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389
Toledo JB, Vanderstichele H, Figurski M et al (2011) Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122(4):401–413
Urwin H, Josephs KA, Rohrer JD et al (2011) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120(1):33–41
Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67(6):555–564
van Harten AC, Kester MI, Visser PJ et al (2011) Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49(3):353–366
Vemuri P, Wiste HJ, Weigand SD et al (2010) Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75(2):143–151
Venables WN and Ripley BD (2002). In: Chambers WEJ, Hardle W, Sheather S, Tierney L (eds) Modern applied statistics with S. Springer Verlag, New York
Winton MJ, Lee EB, Sun E et al (2011) Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J Neurosci 31(21):7691–7699
Xie SX, Ewbank DC, Chittams J et al (2009) Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. Alzheimer Dis Assoc Disord 23(3):268–274
Xie SX, Libon DJ, Wang X et al (2010) Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer’s disease. J Int Neuropsychol Soc 16(2):278–286
Xie SX, Baek Y, Grossman M et al (2011) Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement 7(4):e84–e93
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4